i need to compare two trials Dream 7 and Majestec 3

Created using ChatSlide

The presentation provides a comprehensive analysis of two pivotal oncology trials: the Dream 7 and Majestec 3 trials. The Dream 7 trial investigates the efficacy of belantamab mafodotin with 494 participants, focusing on progression-free and overall survival outcomes. Meanwhile, the Majestec 3 trial explores the effectiveness of teclistamab with a cohort of 587, assessing progression-free survival and complete response rates. By comparing results such as survival metrics and adverse events,...